N-methyL-D-aspartate (NMDA) receptor antagonists, such as ketamine and phencyclidine, induce perceptual abnormalities, psychosis-like symptoms, and mood changes in healthy humans and patients with schizophrenia. The similarity between NMDA receptor antagonist-induced psychosis and schizophrenia has led to the widespread use of the drugs to provide models to aid the development of novel treatments for the disorder. This review investigates the predictive validity of NMDA receptor antagonist models based on a range of novel treatments that have now reached clinical trials. Furthermore, it considers the extent to which the different hypotheses that have been proposed to account for the psychotomimetic effects of NMDA receptor antagonist have been validated by the results of these trials. Finally, the review discusses some of the caveats associated with use of the models and some suggestions as to how a greater use of translational markers might ensure progress in understanding the relationship between the models and schizophrenia.
Abdul-Monim Z. , Reynolds G.P. , Neill J.C. (2003) The atypical antipsychotic ziprasidone, but not haloperidol, improves PCP-induced cognitive deficits in a reversal learning task in the rat . J Psychopharmacology17: 57—66
2.
Abel K.M. , Allin M.P. , Hemsley D.R. , Geyer M.A. (2003) Low dose ketamine increases prepulse inhibition in healthy men . Neuropharmacology44: 729—737
3.
Adams B. , Moghaddam B. (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine . J Neurosci18: 5545—5554
4.
Adams B.W. , Moghaddam B. (2001) Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex . Biol Psychiatry50: 750—757
5.
Adler C.M. , Malhotra A.K. , Elman I. , Goldberg T. , Egan M. , Pickar D. , Breier A. (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia . Am J Psych156: 1646—1649
6.
Aghajanian G.K. , Marek G.J. (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells . Neuropharmacology36: 589—599
7.
Aghajanian G.K. , Marek G.J. (1999) Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release . Brain Res825: 161—171
8.
Allen R.M. , Young S.J. (1978) Phencyclidine-induced psychosis . Am J Psychiatry135: 1081—1084
9.
Anand A. , Charney D. , Oren D. , Berman R. , Hu X. , Cappiello A. , Krystal J. (2000a) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine . Arch Gen Psych57: 270—276
10.
Anand A. , Charney D. , Oren D. , Berman R. , Hu X. , Cappiello A. , Krystal J. (2000b) Potentiation of mood elevating effects of ketamine by lamotrigine: support for the mood elevating effect of inhibition of glutamatergic transmission . XXII CINP Congress, P16.024
11.
Andersen J.D. , Pouzet B. (2004) Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine . Neuropsychopharmacology29: 1080—1090
12.
Aronica E. , Gorter J.A. , Ijlst-Keizers H. , Rozemuller A.J. , Yankaya B. , Leenstra S. , Troost D. (2003) Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins . Eur J Neurosci17: 2106—2118
13.
Arvanov V.L. , Liang X. , Schwartz J. , Grossman S. , Wang R.Y. (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor mediated neurotransmission in rat prefrontal cortical neurons in vitro . J Pharmacol Exp Ther283: 226—234
14.
Audet M.C. , Goulet S. , Dore F.Y. (2005) Repeated subchronic exposure to phencyclidine elicits excessive atypical grooming in rats . Behav Brain Res Oct 26; Epub
15.
Bakker C.B. , Amini F.B. (1961) Observations on the psychotomimetic effects of Sernyl . Comprehensive Psychiatry2: 269—280
16.
Ballmaier M. , Zoli M. , Mazzoncini R. , Gennarelli M. , Spano F. (2001) Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle . Psychopharmacology159: 105—110
17.
Basan A. , Leucht S. (2004) Valproate for schizophrenia. Cochrane Database Syst Rev 1: CD004028
18.
Battaglia G. , Monn J.A. , Schoepp D.D. (1997) In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats . Neurosci Lett229: 161—164
19.
Becker A. , Grecksch G. (2004) Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity . Prog Neuropsychopharmacol Biol Psychiatry28: 1267—1277
20.
Benes F.M. (2000) Emerging principles of altered neural circuitry in schizophrenia . Brain Res Brain Res Rev31: 251—269
21.
Billingslea E.N. , Mastropaolo J. , Rosse R.B. , Bellack A.S. , Deutsch S.I. (2003) Interaction of stress and strain on glutamatergic neurotransmission: relevance to schizophrenia . Pharmacol Biochem Behav74: 351—356
22.
Braff D. , Stone C. , Callaway E. , Geyer M. , Glick I. , Bali L. ( 1978) Prestimulus effects on human startle reflex in normals and schizophrenics . Psychophysiology15: 339—343
23.
Braff D.L. , Grillon C. , Geyer M.A. (1992) Gating and habituation of the startle reflex in schizophrenic patients. Archives ofGeneral Psychiatry49: 206—215
24.
Breese G.R. , Knapp D.J. , Moy S.S. (2002) Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness . Neurosci Biobehav Rev26: 441—455
25.
Brewerton T.D. (1997) The phenomenology of psychosis associated with complex partial seizure disorder . Ann Clin Psychiatry9: 31—51
26.
Brody S.A. , Geyer, M.A. , Large C.H. (2003) Lamotrigine reverses ketamine but not amphetamine-induced deficits in prepulse inhibition in mice . Psychopharmacology169: 240—246
27.
Brody S.A. , Conquet F. , Geyer M.A. (2004) Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice . Psychopharmacology172: 187—195
28.
Capogna M. (2004) Distinct properties of presynaptic group II and III metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs . Eur J Neurosci19: 2847—2858
29.
Carlsson M.L. , Martin P. , Nilsson M. , Sorensen S.M. , Carlsson A. , Waters S. , Waters N. (1999) The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice . J Neural Transm106: 123—129
30.
Carpenter W.T. , Kurz R. , Kirkpatrick B. , Hanlon T.E. , Summerfelt A.T. , Buchanan R.W. , Waltrip R.W. , Breier A. (1991) Carbamazepine maintenance treatment in outpatient schizophrenics . Arch Gen Psychiatry48: 69—72
31.
Carpenter W.T. Jr , Buchanan R.W. , Kirkpatrick B. , Breier A.F. (1999) Diazepam treatment of early signs of exacerbation in schizophrenia . Am J Psychiatry156: 299—303
32.
Casey D.E. , Daniel D.G. , Wassef A.A. , Tracy K.A. , Wozniak P. , Sommerville K.W. (2003) Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia . Neuropsychopharmacology28: 182—192
33.
Ceglia I. , Carli M. , Baviera M. , Renoldi G. , Calcagno E. , Invernizzi R.W. (2004) The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC . J Neurochem91: 189—199
34.
Chavez-Noriega L.E. , Schaffhauser H. , Campbell U.C. (2002) Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia . Curr Drug Targets CNS Neurol Disord1: 261—281
35.
Chen L. , Yang C.R. (2002) Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex . J Neurophysiol87: 2324—2336
36.
Citrome L. , Levine J. , Allingham B. (2000) Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998 . Psychiatric Services51: 634—638
37.
Citrome L. , Casey D.E. , Daniel D.G. , Wozniak P. , Kochan L.D. , Tracy K.A. (2004) Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone . Psychiatry Serv55: 290—294
38.
Clementz B.A. , Blumenfeld L.D. , Cobb S. ( 1997) The gamma band response may account for poor P50 suppression in schizophrenia . Neuroreport8: 3889—3893
39.
Collett V.J. , Collingridge G.L. (2004) Interactions between NMDA receptors and mGlu5 receptors expressed in HEK293 cells . Br J Pharmacol142: 991—1001
40.
Connolly P.M. , Maxwell C. , Liang Y. , Kahn J.B. , Kanes S.J. , Abel T. , Gur R.E. , Turetsky B.I. , Siegel S.J. (2004) The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components . Neurochem Res29: 1179—1188
41.
Corbett R. , Camacho F. , Woods A.T. , Kerman L.L. , Fishkin R.J. , Brooks K. , Dunn R.W. (1995) Antipsychotic agents antagonise non-competitive NMDA antagonist-induced behaviours . Psychopharmacology120: 67—74
42.
Costa E. , Davis J.M. , Dong E. , Grayson D.R. , Guidotti A. , Tremolizzo L. , Veldic M. (2004) A GABAergic cortical deficit dominates schizophrenia pathophysiology . Crit Rev Neurobiol16: 1—23
43.
Coward D.M. (1992) General pharmacology of clozapine . Br J Psychiatry Suppl 17: 5—11
44.
Coyle J.T. , Tsai G. , Goff D. ( 2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia . Ann N Y Acad Sci1003: 318—327
45.
Creese I. , Burt D.R. , Snyder S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs . Science192: 481—483
46.
Crook J.M. , Akil M. , Law B.C. , Hyde T.M. , Kleinman J.E. (2002) Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects . Mol Psychiatry7: 157—164
47.
Daly D.A. , Moghaddam B. (1993) Action of clozapine and haloperidol on extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats . Neurosci Lett152: 61—64
48.
Davis J.M. , Chen N. ( 2004) Dose response and dose equivalence of antipsychotics . J Clin Psychopharmacol24: 192—208
49.
Davis K.L. , Kahn R.S. , Ko G. , Davidson M. (1991) Dopamine in schizophrenia: a review and reconceptualization . Am J Psychiatry148: 1474—1486
50.
Deakin F.W. , Simpson M.D. , Slater P. , Hellewell J.S. (1997) Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia . J Psychopharmacol11: 133—142
51.
Deakin J.F. , Simpson M.D. (1997) A two-process theory of schizophrenia: evidence from studies in post-mortem brain . J Psychiatr Res31: 277—295
52.
de Paulis T. (2001) M-100907 (Aventis) . Curr Opin Investig Drugs2: 123—132
53.
Depoortere R. , Dargazanli G. , Estenne-Bouhtou G. , Coste A. , Lanneau C. , Desvignes C. , Poncelet M. , Heaulme M. , Santucci V. , Decobert M. , Cudennec A. , Voltz C. , Boulay D. , Terranova J.P. , Stemmelin J. , Roger P. , Marabout B. , Sevrin M. , Vige X. , Biton B. , Steinberg R. , Francon D. , Alonso R. , Avenet P. , Oury-Donat F. , Perrault G. , Griebel G. , George P. , Soubrie P. , Scatton B. (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic . Neuropsychopharmacology30: 1963—1985
54.
Devon R.S. , Anderson S. , Teague P.W. , Muir W.J. , Murray V. , Pelosi A.J. , Blackwood D.H. , Porteous D.J. (2001) The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia . Mol Psychiatry6: 311—314
55.
Diaz P. , Bhaskara S. , Dursun S.M. , Deakin B. (2005) Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results . J Clin Psychopharmacol25: 277—278
56.
Dose M. , Hellweg R. , Yassouridis A. , Theison M. , Emrich H.M. (1998) Combined treatment of schizophrenic psychoses with haloperidol and valproate . Pharmacopsychiatry31: 122—125
57.
Dugladze T. , Lepsveridze E. , Breustedt J. , Kehrer C. , Heinemann U. , Gloveli T. (2004) Effects of phencyclidine on signal transfer from the entorhinal cortex to the hippocampus in rats . Neurosci Lett354: 185—188
58.
Dunah A.W. , Standaert D.G. (2001) Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane . J Neurosci21: 5546—5558
59.
Duncan G.E. , Miyamoto S. , Leipzig J.N. , Lieberman J.A. (1999a) Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine . Brain Res843: 171—183
60.
Duncan G.E. , Zorn S. , Lieberman J.A. (1999b) Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia . Mol Psych4: 418—428
61.
Duncan E.J. , Madonick S.H. , Parwani A. , Angrist B. , Rajan R. , Chakravorty S. , Efferen T.R. , Szilagyi S. , Stephanides M. , Chappell P.B. , Gonzenbach S. , Ko G.N. , Rotrosen J.P. (2001) Clinical and sensorimotor gating effects of ketamine in normals . Neuropsychopharmacology25: 72—83
62.
Dursun S.M. , McIntosh D. (1999) Clozapine plus lamotrigine in treatment-resistant schizophrenia . Arch Gen Psychiatry56: 950
63.
Dursun S.M. , Deakin J.F. (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study . J Psychopharmacol15: 297—301
64.
Eichhammer P. , Wiegand R. , Kharraz A. , Langguth B. , Binder H. , Hajak G. (2004) Cortical excitability in neuroleptic-naive first-episode schizophrenic patients . Schizophr Res67: 253—259
65.
Evins A.E. , Amico E. , Posever T.A. , Toker R. , Goff D.C. (2002) D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia . Schizophr Res56: 19—23
66.
Fellin T. , Pascual O. , Gobbo S. , Pozzan T. , Haydon P.G. , Carmignoto G. (2004) Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors . Neuron43: 729—743
67.
Flores-Hernandez J. , Cepeda C. , Hernandez-Echeagaray E. , Calvert C.R. , Jokel E.S. , Fienberg A.A. , Greengard P. , Levine M.S. (2002) Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32 . J Neurophysiol88: 3010—3020
68.
French E.D. (1994) Phencyclidine and the midbrain dopamine system: electrophysiology and behavior . Neurotoxicol Teratol16: 355—362
69.
Galici R. , Echemendia N.G. , Rodriguez A.L. , Conn P.J. (2005) A selective allosteric potentiator of mGlu2 receptors has similar effects to an orthosteric mGlu2/3 agonist in mouse models predictive of antipsychotic activity . J Pharmacol Exp Ther Aug 25: Epub
70.
Gallinat J. , Winterer G. , Herrmann C.S. , Senkowski D. (2004) Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing . Clin Neurophysiol115: 1863—1874
71.
Gardner D.M. , Baldessarini R.J. , Waraich P. (2005) Modern antipsychotic drugs: a critical overview . CMAJ172: 1703—1711
72.
Gewirtz J.C. , Marek G.J. (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors . Neuropsychopharmacology23: 569—576
73.
Geyer M.A. , Segal D.S. , Greenberg B.D. (1984) Increased startle responding in rats treated with phencyclidine . Neurobehav. Toxicol Teratol6: 1—4
74.
Geyer M.A. , Krebs-Thomson K. , Braff D.L. , Swerdlow N.R. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review . Psychopharmacology156: 117—154
75.
Gleason S. , Shannon H. (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice . Psychopharmacology129: 79—84
76.
Goff D.C. , Tsai G. , Manoach D.S. , Flood J. , Darby D.G. , Coyle J.T. (1996) D-cycloserine added to clozapine for patients with schizophrenia . Am J Psychiatry153: 1628—1630
77.
Goff D.C. , Tsai G. , Levitt J. , Amico E. , Manoach D. , Schoenfeld D.A. , Hayden D.L. , McCarley R. , Coyle J.T. (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia . Arch Gen Psychiatry56: 21—27
78.
Goff D.C. , Coyle J.T. (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia . Am J Psychiatry158: 1367—1377
79.
Goldberg T.E. , Weinberger D.R. (1988) Probing prefrontal function in schizophrenia with neuropsychological paradigms . Schizophr Bull14: 179—183
80.
Gouzoulis-Mayfrank E. , Heekeren K. , Neukirch A. , Stoll M. , Stock C. , Obradovic M. , Kovar K.A. (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers . Pharmacopsychiatry38: 301—311
81.
Grace A.A. (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia . Neuroscience41: 1—24
82.
Greene R. (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia . Hippocampus11: 569—577
83.
Guidotti A. , Auta J. , Davis J.M. , Dong E. , Grayson D.R. , Veldic M. , Zhang X. , Costa E. (2005) GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon . Psychopharmacology180: 191—205
84.
Gupta D.S. , McCullumsmith R.E. , Beneyto M. , Haroutunian V. , Davis K.L. , Meador-Woodruff J.H. (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia . Synapse57: 123—131
85.
Habara T. , Hamamura T. , Miki M. , Ohashi K. , Kuroda S. (2001) M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain . Eur J Pharmacol417: 189—194
86.
Harrison P.J. , Owen M.J. (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications . Lancet361: 417—419
87.
Heresco-Levy U. , Javitt D.C. , Ermilov M. , Silipo G. , Shimoni J. (1998) Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia . Int J Neuropsychopharmacol1: 131—135
88.
Heresco-Levy U. (2000) N-methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade . Int J Neuropsychopharmacol3: 243—258
89.
Heresco-Levy U. , Ermilov M. , Shimoni J. , Shapira B. , Silipo G. , Javitt D.C. (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia . Am J Psychiatry159: 480—482
90.
Heresco-Levy U. (2003) Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuro-PsychopharmBiol Psych27: 1113—1123
91.
Heresco-Levy U. , Javitt D.C. (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis . Schizophr Res66: 89—96
92.
Heresco-Levy U. , Javitt D.C. , Ebstein R. , Vass A. , Lichtenberg P. , Bar G. , Catinari S. , Ermilov M. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia . Biol Psychiatry57: 577—585
93.
Herrling P. (1994) D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans . Neuropsychopharm10: 591S
94.
Hesslinger B. , Normann C. , Langosch J.M. , Klose P. , Berger M. , Walden J. (1999) Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients . J Clin Psychopharmacol19: 310—315
95.
Hetem L.A. , Danion J.M. , Diemunsch P. , Brandt C. (2000) Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers . Psychopharmacology152: 283—288
96.
Holcomb H.H. , Lahti A.C. , Medoff D.R. , Cullen T. , Tamminga C.A. (2005) Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia . Neuropsychopharmacology30: 2275—2282
97.
Homayoun H. , Stefani M.R. , Adams B.W. , Tamagan G.D. , Moghaddam B. (2004) Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine releaseNeuropsychopharmacology29: 1259—1269
98.
Homayoun H. , Moghaddam B. (2005) Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors . Cereb Cortex Apr 20: Epub
99.
Homayoun H. , Jackson M.E. , Moghaddam B. (2005) Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats . J Neurophysiol93: 1989—2001
100.
Honey G.D. , O'loughlin C. , Turner D.C. , Pomarol-Clotet E. , Corlett P.R. , Fletcher P.C. (2005a) The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia . Neuropsychopharmacology Aug 3: Epub ahead of print
101.
Honey G.D. , Honey R.A. , Sharar S.R. , Turner D.C. , Pomarol-Clotet E. , Kumaran D. , Simons J.S. , Hu X. , Rugg M.D. , Bullmore E.T. , Fletcher P.C. (2005b) Impairment of specific episodic memory processes by subpsychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task . Psychopharmacology181: 445—457
102.
Hunt M.J. , Kessal K. , Garcia R. (2005) Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats . J Neurosci25: 524—531
103.
Idris N.F. , Dawson L.A. , Hughes Z.A. , de la Flor R. , Jones D N C , Large C.H. , Kalinichev M. , Neill J.C. (2004) Effects of lamotrigine, clozapine, and haloperidol on PCP-induced changes in steady state brain tissue amino acid levels in the rat . Society for Neuroscience Abstracts 695.9
104.
Idris N.F. , Repeto P. , Neill J.C.Large C.H. (2005) Investigation of the effects of lamotrigine and clozapine to improve reversal learning impairments induced by acute PCP and d-amphetamine in the rat . Psychopharmacology179: 336—348
105.
Itokawa M. , Yamada K. , Yoshitsugu K. , Toyota T. , Suga T. , Ohba H. , Watanabe A. , Hattori E. , Shimizu H. , Kumakura T. , Ebihara M. , Meerabux J.M. , Toru M. , Yoshikawa T. (2003) A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia . Pharmacogenetics13: 271—278
106.
Jackson M.E. , Homayoun H. , Moghaddam B. (2004) NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex . PNAS101: 8467—8472
107.
Javitt D.C. , Balla A. , Sershen H. , Lajtha A. (1999) A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors . Biol Psychiatry45: 668—679
108.
Javitt D.C. , Lindsley R.W. (2001) Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque . Psychopharmacology156: 165—168
109.
Javitt D.C. , Duncan L. , Balla A. , Sershen H. (2004a) Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action . Mol Psychiatry: Epub
110.
Javitt D.C. , Balla A. , Burch S. , Suckow R. , Xie S. , Sershen H. (2004b) Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists . Neuropsychopharmacology29: 300—307
111.
Jentsch J.D. , Anh Tran , Dung Lee , Youngren K.D. , Roth R.H. (1997) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilisation and impairs prefrontal cortical-dependent cognition in the rat . Neuropsychopharmacology17: 92—99
112.
Jentsch J. , Roth R. ( 1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia . Neuropsychopharmacology20: 201—225
113.
Jentsch J.D. , Taylor J.R. (2001) Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats . Neuropsychopharmacology24: 66—74
114.
Jentsch J.D. , Anzivino L.A. (2004) A low dose of the alpha2 agonist clonidine ameliorates the visual attention and spatial working memory deficits produced by phencyclidine administration to rats . Psychopharmacology175: 76—83
115.
Jodo E. , Suzuki Y. , Katayama T. , Hoshino K.Y. , Takeuchi S. , Niwa S. , Kayama Y. (2005) Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway . Cereb Cortex15: 663—669
116.
Johnson J.W. , Ascher P. (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons . Nature325: 529—531
117.
Kane J. , Honigfeld G. , Singer J. , Meltzer H. (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine . Arch Gen Psychiatry45: 789—796
118.
Kapur S. , Seeman P. (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia . Mol Psychiatry7: 837—844
119.
Karper L.P. , Grillon C. , Morrissey K. , Abi-Saab D. , Morgan C.A. , Charney D.S. , Krystal J.H. (1994) The effect of ketamine on the acoustic startle response . Society for Neuroscience Abstracts20: 482
120.
Kegeles L.S. , Abi-Dargham A. , Zea-Ponce Y. , Rodenhiser-Hill J. , Mann J.J. , Van Heertum R.L. , Cooper T.B. , Carlsson A. , Laruelle M. (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia . Biol Psychiatry48: 627—640
121.
Kilbride J. , Huang L.Q. , Rowan M.J. , Anwyl R. (1998) Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV . Eur J Pharmacol356: 149—157
122.
Kinney G.G. , Burno M. , Campbell U.C. , Hernandez L.M. , Rodriguez D. , Bristow L.J. , Conn P.J. (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents . J Pharmacol Exp Ther306: 116—123
123.
Kinney G.G. , O'Brien J.A. , Lemaire W. , Burno M. , Bickel D.J. , Clements M.K. , Chen T.B. , Wisnoski D.D. , Lindsley C.W. , Tiller P.R. , Smith S. , Jacobson M.A. , Sur C. , Duggan M.E. , Pettibone D.J. , Conn P.J. , Williams D.L. Jr (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models . J Pharmacol Exp Ther313: 199—206
124.
Ko G.N. , Korpi E.R. , Freed W.J. , Zalcman S.J. , Bigelow L.B. (1985) Effect of valproic acid on behaviour and plasma amino acid concentrations in chronic schizophrenic patients . Biol Psychiatry20: 199—228
125.
Konradi C. , Heckers S. (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment . Pharmacol Ther97: 153—179
126.
Kremer I. , Vass A. , Gorelik I. , Bar G. , Blanaru M. , Javitt D.C. , Heresco-Levy U. (2004) Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia . Biol Psych56: 441—444
127.
Krystal J.H. , Bennett A. , Abi-Saab D. , Belger A. , Karper L.P. , D'Souza D.C. , Lipschitz D. , Abi-Dargham A. , Charney D.S. (2000) Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions . Biol Psychiatry47: 137—143
128.
Krystal J.H. , D'Souza D.C. , Mathalon D. , Perry E. , Belger A. , Hoffman R. (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development . Psychopharmacology169: 215—233
129.
Krystal J.H. , Abi-Saab W. , Perry E. , D'Souza D.C. , Liu N. , Gueorguieva R. , McDougall L. , Hunsberger T. , Belger A. , Levine L. , Breier A. (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects . Psychopharmacology179: 303—309
130.
Kuo C-C. (1998) A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuron neuronal Na+ channels . Mol Pharm54: 712—721
131.
Kuroki T. , Kawahara T. , Yonezawa Y. , Tashiro N. (1999) Effects of the serotonin2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex . Prog Neuropsychopharmacol Biol Psychiatry23: 1259—1275
132.
Kwang-Hyuk L. , Williams L.M. , Breakspear M. , Gordon E. (2003) Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia . Brain Res Rev41: 57—78
Lahti A.C. , Koffel B. , LaPorte D. , Tamminga C.A. (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia . Neuropsychopharmacology13: 9—19
135.
Lahti A.C. , Weiler M.A. , Tamara Michaelidis B.A. , Parwani A. , Tamminga C.A. (2001) Effects of ketamine in normal and schizophrenic volunteers . Neuropsychopharmacology25: 455—467
136.
Large C.H. , Webster E.L. , Goff D.C. (2005) The potential role of lamotrigine in schizophrenia . Psychopharmacology181: 415—436
137.
Laruelle M. , Kegeles L.S. , Abi-Dargham A. (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment . Ann N Y Acad Sci1003: 138—158
138.
Lees J. , Hallak J.E. , Deakin J.F. , Dursun S.M. (2004) Gender differences and the effects of ketamine in healthy volunteers . J Psychopharmacol18: 337—339
139.
Le Pen G. , Grottick A.J. , Higgins G.A. , Moreau J.L. (2003) Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia . Neuropsychopharmacology28: 1799—1809
140.
Lewis D.A. (2000) GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia . Brain Res Rev31: 270—276
141.
Lewis D.A. , Glantz L.A. , Pierri J.N. , Sweet R.A. (2003) Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons . Ann N Y Acad Sci1003: 102—112
142.
Lieberman J.A. , Stroup T.S. , McEvoy J.P. , Swartz M.S. , Rosenheck R.A. , Perkins D.O. , Keefe R.S. , Davis S.M. , Davis C.E. , Lebowitz B.D. , Severe J. , Hsiao J.K. ; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia . N Engl J Med353: 1209—1223
143.
Linn G.S. , O'Keeffe R.T. , Schroeder C.E. , Lifshitz K. , Javitt D.C. (1999) Behavioral effects of chronic phencyclidine in monkeys . Neuroreport10: 2789—2793
144.
Lorrain D.S. , Baccei C.S. , Bristow L.J. , Anderson J.J. , Varney M.A. (2003a) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 . Neuroscience117: 697—706
145.
Lorrain D.S. , Schaffhauser H. , Campbell U.C. , Baccei C.S. , Correa L.D. , Rowe B. , Rodriguez D.E. , Anderson J.J. , Varney M.A. , Pinkerton A.B. , Vernier J.M. , Bristow L.J. (2003b) Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge . Neuropsychopharmacology28: 1622—1632
146.
Lublin H. , Eberhard J. , Levander S. (2005) Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics . Int Clin Psychopharmacol20: 183—198
147.
Ma J. , Leung L.S. (2000) Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine . Behav Brain Res111: 1—11
148.
Maeda J. , Suhara T. , Okauchi T. , Semba J. (2003) Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex . Neurosci Lett336: 171—174
149.
Makino C. , Shibata H. , Ninomiya H. , Tashiro N. , Fukumaki Y. (2005) Identification of single-nucleotide polymorphisms in the human N-methyl-D-aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia . Psychiatr Genet15: 215—221
150.
Malhotra A. , Pinals D. , Adler C. , Elman I. , Clifton A. , Pickar D. , Breier A. (1997a) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics . Neuropsychopharmacology17: 141—150
151.
Malhotra A. , Adler C. , Kennison S. , Elman I. , Pickar D. , Breier A. (1997b) Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine . Biol Psychiatry42: 664—668
152.
Marcus M.M. , Jardemark K.E. , Wadenberg M.L. , Langlois X. , Hertel P. , Svensson T.H. (2005) Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat . Int J Neuropsychopharmacol8: 315—327
153.
Marrs W. , Kuperman J. , Avedian T. , Roth R.H. , Jentsch J.D. (2005) Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats . Neuropsychopharmacology30: 1500—1510
154.
Martin P. , Carlsson M.L. , Hjorth S. (1998) Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats . Neuroreport9: 2985—2988
155.
Maxwell C.R. , Ehrlichman R.S. , Liang Y. , Trief D. , Kanes S.J. , Karp J. , Siegel S.J. (2005) Ketamine produces lasting disruptions in encoding of sensory stimuli . J Pharmacol Exp Ther Sep 28: Epub ahead of print
156.
Medoff D.R. , Holcomb H.H. , Lahti A.C. , Tamminga C.A. (2001) Probing the human hippocampus using rCBF: contrasts in schizophrenia . Hippocampus11: 543—550
157.
Millan M.J. (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives . Psychopharmacology179: 30—53
158.
Mirjana C. , Baviera M. , Invernizzi R.W. , Balducci C. (2004) The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex . Neuropsychopharmacology29: 1637—1647
159.
Miyamoto S. , Mailman R.B. , Lieberman J.A. , Duncan G.E. (2001) Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors . Brain Res894: 167—180
160.
Moghaddam B. , Adams B. , Verma A. , Daly D. ( 1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with prefrontal cortex . J Neurosci17: 2921—2927
161.
Moghaddam B. , Adams B.W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats . Science281: 1349—1352
162.
Morari M. , O'Connor W.T. , Ungerstedt U. , Fuxe K. ( 1994) Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid . Eur J Pharmacol256: 23—30
163.
Morris B.J. , Cochran S.M. , Pratt J.A. (2005) PCP: from pharmacology to modelling schizophrenia . Curr Opin Pharmacol5: 101—106
164.
Muly E.C. , Maddox M. , Smith Y. (2003) Distribution of mGluR1alpha and mGluR5 immunolabeling in primate prefrontal cortex . J Comp Neurol467: 521—535
165.
Nelson C.L. , Burk J.A. , Bruno J.P. , Sarter M. (2002) Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats . Psychopharmacology161: 168—179
166.
Neppe V.M. (1983) Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities . J Clin Psychiatry44: 326—331
167.
Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNSDrugs19 (Suppl 1): 1—93
168.
Nilsson M. , Carlsson A. , Carlsson M.L. (1997) Glycine and D-serine decrease MK-801-induced hyperactivity in mice . J Neural Transm104: 1195—1205
169.
Ninan I. , Jardemark K.E. , Wang R.Y. (2003) Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex . Neuropharmacology44: 462—472
170.
Ninan I. , Wang R.Y. (2003) Modulation of the ability of clozapine to facilitate NMDA-and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence . Eur J Neurosci17: 1306—1312
171.
Olney J.W. , Farber N.B. (1995) Glutamate receptor dysfunction and schizophrenia . Arch Gen Psychiatry52: 998—1007
172.
Olney J.W. , Newcomer J.W. , Farber N.B. (1999) NMDA receptor hypofunction model of schizophrenia . J Psychiatr Res33: 523—533
173.
Olney J.W. (2002) New insights and new issues in developmental neurotoxicology . Neurotoxicology23: 659—668
174.
Olszewski R.T. , Bukhari N. , Zhou J. , Kozikowski A.P. , Wroblewski J.T. , Shamimi-Noori S. , Wroblewska B. , Bzdega T. , Vicini S. , Barton F.B. , Neale J.H. (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR . J Neurochem89: 876—885
175.
Ong J.C. , Brody S. , Large C. , Geyer M.A. (2005) An investigation of the effects of mood stabilizers on murine prepulse inhibition deficits induced by dopamine or glutamate dysregulation . J Pharmacol Exp Ther Aug 25: Epub
176.
Oranje B. , van Berckel B.N. , Kemner C. , van Ree J.M. , Kahn R.S. , Verbaten M.N. (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention . Neuropsychopharmacology22: 293—302
177.
Ossowska K. , Pietraszek M. , Wardas J. , Nowak G. , Wolfarth S. (1999) Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats . Naunyn Schmiedebergs Arch Pharmacol359: 280—287
178.
Overton P.G. , Clark D. (1997) Burst firing in midbrain dopaminergic neurons . Brain Res Rev25: 312—334
179.
Perry W. , Braff D.L. (1994) Information-processing deficits and thought disorder in schizophrenia . Am J Psychiatry151: 363—367
180.
Perry W. , Geyer M.A. , Braff D.L. (1999) Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients . Arch Gen Psychiatry56: 277—281
181.
Podhorna J. , Didriksen M. (2005) Performance of male C57BL/6J mice and Wistar rats in the water maze following various schedules of phencyclidine treatment . Behav Pharmacol16: 25—34
182.
Rainey J M J , Crowder M.K. (1975) Prolonged psychosis attributable to phencyclidine: A report of three cases . Am J Psychiatry132: 1076—1078
183.
Rice S.R. , Niu N. , Berman D.B. , Heston L.L. , Sobell J.L. (2001) Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients . Mol Psychiatry6: 274—284
184.
Richardson-Burns S.M. , Haroutunian V. , Davis K.L. , Watson S.J. , Meador-Woodruff J.H. (2000) Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus . Biol Psychiatry47: 22—28
185.
Risterucci C. , Jeanneau K. , Schoppenthau S. , Bielser T. , Kunnecke B. , von Kienlin M. , Moreau J.L. (2005) Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia . Psychopharmacology180: 724—734
186.
Rodrigues R.J. , Alfaro T.M. , Rebola N. , Oliveira C.R. , Cunha R.A. (2005) Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum . J Neurochem92: 433—441
187.
Rogawski M.A. , Loscher W. (2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions . Nat Medicine10: 685—692
Rowland L.M. , Bustillo J.R. , Mullins P.G. , Jung R.E. , Lenroot R. , Landgraf E. , Barrow R. , Yeo R. , Lauriello J. , Brooks W.M. (2005b) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study . Am J Psychiatry162: 394—396
190.
Sakurai K. , Toru M. , Yamakawa-Kobayashi K. , Arinami T. (2000) Mutation analysis of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia . Neurosci Lett296: 168—170
191.
Sams-Dodd F. (1998) Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test . Neurosci Biobehav Rev23: 287—293
192.
Schoepp D.D. , Marek G.J. (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schiozophrenia ? Current Drug Targets — CNS Neurological Disorders1: 215—225
193.
Seeman P. (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 . Neuropsychopharmacology7: 261—284
194.
Seeman P. (2002) Atypical antipsychotics: mechanisms of action . Can J Psychiatry47: 27—38
195.
Seeman P. , Lasaga M. (2005) Dopamine agonist action of phencyclidine . Synapse58: 275—277
196.
Seeman P. , Ko F. , Tallerico T. (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics . Mol Psychiatry10: 877—883
197.
Shi W.X. , Zhang X.X. (2003) Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine . J Pharmacol Exp Ther305: 680—687
198.
Soyka M. , Koch W. , Moller H.J. , Ruther T. , Tatsch K. (2005) Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients Results from a FDG-PET study . Eur Arch Psychiatry Clin Neurosci255: 308—312
199.
Spielewoy C. , Markou A. (2004) Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: relevance to smoking in schizophrenia patients . Behav Genet34: 343—354
200.
Steinpreis R.E. (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis . Behav Brain Res74: 45—55
201.
Stoet G. , Snyder L.H. (2005) Effects of the NMDA Antagonist ketamine on task-switching performance: evidence for specific impairments of executive control . Neuropsychopharmacology Oct 5: Epub
202.
Sutula T.P. , Hagen J. , Pitkanen A. (2003) Do epileptic seizures damage the brain?Curr Opin Neurol16: 189—195
203.
Svenningsson P. , Tzavara E.T. , Carruthers R. , Rachleff I. , Wattler S. , Nehls M. , McKinzie D.L. , Fienberg A.A. , Nomikos G.G. , Greengard P. (2003) Diverse psychotomimetics act through a common signaling pathway . Science302: 1412—1415
204.
Svensson T.H. (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs . Brain Res Rev31: 320—329
205.
Symond M.P. , Harris A.W. , Gordon E. , Williams L.M. (2005) “ Gamma synchrony” in first-episode schizophrenia: a disorder of temporal connectivity ? Am J Psychiatry162: 459—465
206.
Takahata R. , Moghaddam B. (1998) Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex . J Neurochem71: 1443—1449
207.
Takahata R. , Moghaddam B. (2003) Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine . Neuropsychopharmacology28: 1117—1124
208.
Tamminga C.A. , Tanimoto K. , Kuo S. , Chase T.N. , Contreras P.C. , Rice K.C. , Jackson A.E. , O'Donohue T.L. (1987) PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCPreceptor-acylating agent . Synapse1: 497—504
209.
Tamminga C.A. , Lahti A.C. , Medoff D.R. , Gao X.M. , Holcomb H.H. (2003) Evaluating glutamatergic transmission in schizophrenia . Ann N Y Acad Sci1003: 113—118
210.
Talvik-Lotfi M. , Nyberg S. , Nordstrom A.L. , Ito H. , Halldin C. , Brunner F. , Farde L. (2000) High 5HT2A receptor occupancy in M100907-treated schizophrenic patients . Psychopharmacology148: 400—403
211.
Tauscher J. , Hussain T. , Agid O. , Verhoeff N.P. , Wilson A.A. , Houle S. , Remington G. , Zipursky R.B. , Kapur S. (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics . Am J Psychiatry161: 1620—1625
212.
Tiihonen J. , Hallikainen T. , Ryynanen O-P. , Repo-Tiihonen E. , Kotilainen I. , Eronen M. , Toivonen P. , Wahlbeck K. , Putkonen A. (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial . Biol. Psychiatry54: 1241—1248
213.
Torta R. , Keller R. (1999) Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications . Epilepsia40 (Suppl 10): S2—20
214.
Tremolizzo L. , Doueiri M.S. , Dong E. , Grayson D.R. , Davis J. , Pinna G. , Tueting P. , Rodriguez-Menendez V. , Costa E. , Guidotti A. (2005) Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice . Biol Psychiatry57: 500—509
215.
Tsai G. , Yang P. , Chung L-C. , Lange N. , Coyle J. (1998) D-Serine added to antipsychotics for the treatment of schizophrenia . Biol Psychiatry44: 1081—1089
216.
Tsai G. , Lane H.Y. , Yang P. , Chong M.Y. , Lange N. (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia . Biol Psychiatry55: 452—456
217.
Tuominen H.J. , Tiihonen J. , Wahlbeck K. (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis . Schizophr Res72: 225—234
218.
Umbricht D. , Schmid L. , Koller R. , Vollenweider F.X. , Hell D. , Javitt D.C. (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia . Arch Gen Psychiatry57: 1139—1147
219.
Umbricht D. , Koller R. , Schmid L. , Skrabo A. , Grubel C. , Huber T. , Stassen H. (2003) How specific are deficits in mismatch negativity generation to schizophrenia?Biol Psychiatry53: 1120—1131
220.
Vaisanen J. , Ihalainen J. , Tanila H. , Castren E. (2004) Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia . Cell Mol Neurobiol24(6): 769—780
221.
van Berckel B.N. , Oranje B. , van Ree J.M. , Verbaten M.N. , Kahn R.S. (1998) The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects . Psychopharmacology137: 271—281
222.
van Berckel B.N. , Kegeles L.S. , Waterhouse R. , Guo N. , Hwang D.R. , Huang Y. , Narendran R. , Van Heertum R. , Laruelle M. (2005) Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography . Neuropsychopharmacology21: Epub
223.
Varty G.B. , Higgins G.A. (1995) Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs . Psychopharmacology122: 15—26
224.
Varty G.B. , Bakshi V.P. , Geyer M.A. (1999) M100907, a serotonin 5HT2A receptor antagonist and putative antipsychotic, blocks dizocilpineinduced prepulse inhibition deficits in Sprague-Dawley and Wistar rats . Neuropsychopharmacol20: 311—321
Weiler M.A. , Thaker G.K. , Lahti A.C. , Tamminga C.A. (2000) Ketamine effects on eye movements . Neuropsychopharmacology23: 645—653
227.
Weinberger D.R. (1999) Cell biology of the hippocampal formation in schizophrenia . Biol Psychiatry45: 395—402
228.
West W.B. , Lou A. , Pechersky K. , Chachich M.E. , Appel J.B. (2000) Antagonism of a PCP drug discrimination by hallucinogens and related drugs . Neuropsychopharmacology22: 618—625
229.
Winter J.C. , Eckler J.R. , Rabin R.A. (2004) Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli . Psychopharmacology172: 233—240
230.
Winterer G. , Weinberger D R (2004) Genes , dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci27: 683—690
231.
Wolf R. , Dobrowolny H. , Matzke K. , Paelchen K. , Bogerts B. , Schwegler H. (2006) Prepulse inhibition is different in two inbred mouse strains (CPB-K and BALB/cJ) with different hippocampal NMDA receptor densities . Behav Brain Res166: 78—84
232.
Xie X. , Lancaster B. , Peakman T. , Garthwaite J. (1995) Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones . Pflugers Arch430: 437—446
233.
Yamada S. , Harano M. , Annoh N. , Nakamura K. , Tanaka M. (1999) Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats . Biol Psychiatry46: 832—838
234.
Yamamoto B.K. , Cooperman M.A. (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations . J Neurosci14: 4159—4166
235.
Yenari M.A. , Bell T.E. , Kotake A.N. , Powell M. , Steinberg G.K. (1998) Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS19755) in neurosurgery patients . Clin. Neuropharm21: 28—34
236.
Youngren K.D. , Inglis F.M. , Pivirotto P.J. , Jedema H.P. , Bradberry C.W. , Goldman-Rakic P.S. , Roth R.H. , Moghaddam B. (1999) Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus . Neuropsychopharmacology20: 403—412
237.
Yu B. , Wang C. , Liu J. , Johnson K.M. , Gallagher J.P. (2002) Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors . Neuroscience113: 1—10
